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Objectives This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension
patients.
Background Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hyperten-
sive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid
baroreflex may help these patients.
Methods Forty-five subjects with systolic blood pressure 160 mm Hg or diastolic 90 mm Hg despite at least 3 antihy-
pertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos ther-
apy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An external program-
mer was used to optimize and individualize efficacy.
Results Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 anti-
hypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This
result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg.
The device exhibited a favorable safety profile.
Conclusions The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidi-
ties receiving numerous medications. This unique therapy offers a safe individualized treatment option for these
high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently
under evaluation in a prospective, placebo-controlled clinical trial. (J Am Coll Cardiol 2010;56:1254–8)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.089a
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tespite the availability of potent antihypertensive medica-
ions, a sizeable proportion of the hypertensive population
emains treatment resistant (1). Early attempts to treat such
atients with electrical carotid sinus nerve stimulation (2–4)
ave been summarized previously (5,6), but these efforts
ere not successful because of technical problems. Recent
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ospital Essen, Essen, Germany. This study was funded by CVRx, Inc., Minneap- advances in device technology and an increasing number of
atients whose hypertension cannot be controlled with
edications have led to renewed interest in this approach.
Recently, a novel implantable device (Rheos System,
VRx, Inc., Minneapolis, Minnesota) has been developed
hat works by electrical stimulation of the carotid sinus (7).
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October 5, 2010:1254–8 Implantable Device for Baroreflex Activationhe device enhances afferent nerve traffic from the barore-
eptors to the cardiovascular control centers in the brain,
hich subsequently reduce sympathetic outflow and blood
ressure (BP). Canine studies have demonstrated sustained
alls in arterial pressure in normotensive and hypertensive
ogs (6,8–10). Observations in patients undergoing elective
arotid surgery have confirmed that short-term activation of
he baroreflex acutely lowers BP in humans (11).
ethods
he DEBuT-HT (Device Based Therapy in Hypertension
rial) was a multicenter, prospective, nonrandomized fea-
ibility study. Its purpose was to assess the safety and efficacy
f the Rheos system over 3 months in resistant hypertensive
ubjects. The medical ethics committees of all participating
enters approved the study protocol, and written informed
onsent was obtained from subjects. After the 3 months,
ubjects consented to an extended follow-up phase.
Subjects were 21 years of age, and BP was 160/90
m Hg despite receiving at least 3 antihypertensive agents,
ncluding a diuretic. Subjects were certified compliant and
edications were kept constant for 2 months before entry
nd during the first 3 months of therapy, except when
edically necessary. Carotid bifurcations were assessed by
ltrasonographic examination to be at or below the C3 to
4 level to ensure operative suitability.
aseline CharacteristicsTable 1 Baseline Characteristics
Total Enrolled
(n  45)
Completed 3-Mo
(n 
Demographics
Sex, male 26 (58) 21 (57
Race, Caucasian 45 (100) 37 (10
Age, yrs 54 9 55
Body mass index, kg/m2 32 6 32
Office measurements
SBP, mm Hg 179 29 179
DBP, mm Hg 105 22 105
HR, beats/min 80 13 80
Antihypertensive treatment
Number 5 (3–9) 5 (3–
Antihypertensive therapy index 38 (10–82) 38 (10
Antihypertensive treatment per class
ACE inhibitor/A2 blocker 41 (91) 34 (92
Beta-blocker 37 (82) 29 (78
Alpha-blocker 21 (47) 16 (43
Calcium-channel blocker 34 (76) 29 (78
Diuretic 45 (100) 37 (10
Sympatholitic 17 (38) 14 (38
Direct vasodilator 5 (11) 3 (8)
Medical history
Cardiovascular disease 34 (76) 28 (76
Diabetes mellitus 14 (31) 11 (30
alues are n (%), mean SD, or median (range). Data presented for all enrolled participants (n 4
herapy.
ACE  angiotensin-converting enzyme; A2  angiotensin 2; DBP  diastolic blood pressure; HR  heaExclusions included baroreflex
ailure, significant orthostatic hy-
otension, cardiac arrhythmias,
hronic atrial fibrillation, clini-
ally significant cardiac valvular
isease or hypertension second-
ry to a treatable cause, carotid
rtery atherosclerosis with 50% stenosis as determined by
ltrasonography, prior implant or radiation in the carotid
inus region, currently implanted electrical medical devices,
ialysis, and pregnancy or contemplating pregnancy.
The Rheos system consists of a pulse generator, 2 leads,
nd a programmer. The implant procedure has been de-
cribed previously (12,13). The device was activated 1
onth after implant, which is the study baseline time point.
t each follow-up visit, therapy was individualized with the
rogrammer to produce an optimal BP reduction.
Subjects were followed up monthly for the first 3 months
nd thereafter at least annually. All information on antihy-
ertensive agents including dosage was recorded. Office BP
easurements were taken at every scheduled visit with a
alidated electronic device, and readings were repeated
hen 2 consecutive measurements varied by 5 mm Hg.
he recorded BP was the mean of the last 2 readings. In
ddition, ambulatory BP measurements were performed
ith at least 40 measurements during 24 h using a validated
evice.
llow-Up Completed 1-Year Follow-Up
(n  26)
Completed 2-Year Follow-Up
(n  17)
14 (54) 8 (47)
26 (100) 17 (100)
53 9 51 9
33 7 31 6
180 31 188 32
108 24 114 23
80 15 81 11
5 (3–9) 5 (3–8)
40 (10-82) 34 (10–56)
24 (92) 16 (94)
21 (81) 14 (82)
11 (42) 6 (35)
21 (81) 12 (71)
26 (100) 17 (100)
10 (39) 6 (35)
3 (12) 1 (6)
21 (81) 13 (76)
9 (35) 3 (18)
for the cohorts that completed 3 months (n 37), 1 year (n 26), and 2 years (n 17) of device
Abbreviations
and Acronyms
BP  blood pressure
SAE  serious adverse
eventnth Fo
37)
)
0)
9
7
28
22
13
9)
–82)
)
)
)
)
0)
)
)
)
5) andrt rate; SBP  systolic blood pressure.
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Implantable Device for Baroreflex Activation October 5, 2010:1254–8An independent committee adjudicated adverse events to
etermine the severity and relationship to the procedure or
evice. Death, life-threatening situation, inpatient hospital-
zation, prolongation of existing hospitalization, or persis-
ent or significant disability were classified as serious adverse
vents (SAEs).
Functional safety measures were recorded at baseline,
fter 3 months, and at 1 year of device therapy, including
atient’s ability to exercise during a 6-min hall walk test,
nd orthostatic blood pressure changes at 1, 3, and 5 min of
pright standing after 5 min in supine position. Orthostatic
ypotension was defined as a fall in BP by at least 20/10 mm
g, within 3 to 5 min of quiet standing. Renal function was
ssessed using serum creatinine as measured by a central
aboratory. Carotid artery ultrasonography was performed to
ssess carotid artery stenosis.
A cohort of 10 eligible patients who for various reasons
eclined participation in this trial were followed up by
egular care. Their physicians recorded office BP, antihy-
ertensive treatment, and SAEs.
tatistical analyses. Data are presented as mean  SD or
ean change  SE unless indicated otherwise. Statistical
nalysis was performed parametrically and 2-sided using
AS version 9.1 statistical software (SAS Institute, Cary,
orth Carolina). A p value 0.05 was considered statisti-
ally significant. The time to first procedure or device-
elated SAE was calculated according to the Kaplan-Meier
ethod. The BP responses were calculated as the difference
etween a follow-up visit and the baseline visit by a paired
test for the cohort of subjects who had reached that visit by
he time of analysis. No adjustments to p values were made
ue to comparisons at multiple visits.
esults
orty-five subjects at 9 clinical centers were implanted
etween March 2004 and November 2007. Subject character-
stics are presented in Table 1. The first 3 subjects enrolled
ere excluded from the safety and efficacy analyses per proto-
ol. Of the remaining 42 subjects, there were 4 dropouts and 1
issed visit, resulting in 37 subjects evaluable. The 4 dropouts
id not differ from the 37 evaluable subjects in any systematic
ay. As of this report, 26 and 17 subjects completed 1 and 2
ears of device therapy, respectively.
All subjects received full doses of antihypertensive med-
cations per standard medical practice. The median number
t baseline was 5 (range 3 to 9). No significant changes
ccurred during the study period.
afety results. Figure 1A shows the percentage of subjects
ho remained free from a procedure- or device-related
AE. Of 42 subjects, 7 experienced a procedure-related
AE and 1 subject experienced a device-related SAE. One
atal procedure-related event occurred 6 days after implant
ue to angioneurotic edema before device activation. The
ause could not be determined definitively, but a drug ueaction is suspected. Three subjects had the device ex-
lanted before activation because of infection. However, in
subject, the leads were not removed, and a device was
eimplanted 12 months later. Three additional procedure-
elated SAEs occurred within 30 days of the original
mplant: perioperative stroke with minimal residual effects,
ongue paresis (no abnormalities on brain magnetic reso-
ance imaging) most likely due to intraoperative injury to
he hypoglossal nerve, and moderate pulmonary edema that
esolved within 6 days. The only device-related SAE was
ue to movement of the implantable pulse generator,
esulting in the need for further surgery to reposition the
mplantable pulse generator, which resolved the problem.
Most procedure-related events were directly related to the
ncision or the anesthetic procedure, and most device-
elated events were related to nonoptimal device placement.
he unrelated SAEs were likely related to subjects’ individ-
Figure 1 Kaplan-Meier Analysis,
Percentage of Participants Free From SAE
(A) Percentage of patients who remained free from a procedure-related serious
adverse event (SAE) (red line) and a device-related SAE (black line). (B) Per-
centages of patients who remained free from a device-unrelated SAE in the sur-
gery group (red line) and the nonsurgery group (black line). The latter group
consists of patients who were eligible but refused device implant.al risks. The percentage of unrelated SAEs in this treated
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October 5, 2010:1254–8 Implantable Device for Baroreflex Activationroup was comparable to the percentage of SAEs in the
ohort of declined participants (Fig. 1B).
Figure 2 presents functional safety measures. Walk dis-
ance at 6-min hall walk at 1 year significantly rose by 48 m
p  0.01) among 14 participants for whom this was
easured. Serum creatinine had significantly increased after
year of therapy in 22 participants. None of the patients
ad carotid artery stenosis at the 1-year visit. No evidence
Figure 2 Functional Safety Results After 3 Months and 1 Year
(A) Distance walked during the 6-min hall walk test, and (B) serum creatinine. Nu
changes at each time point compared with baseline. (C) Orthostatic blood pressu
squares  systolic blood pressure (SBP) baseline; red squares  SBP 3 months;
black triangles  heart rate (HR) baseline; red triangles  HR 3 months.
Blood Pressure Results, Mean Change ()Presented for Office and Ambulatory ReadingsTable 2 Blood Pre sur Results, Mean ChanPresented for Office and Ambulator
 3 Months
Office blood pressure n  37
SBP, mm Hg 21 4 (p 0.001)
DBP, mm Hg 12 2 (p 0.001)
HR, beats/min 8 2 (p 0.001)
Ambulatory blood pressure n  26
SBP, mm Hg 6 3 (p 0.102)
DBP, mm Hg 4 2 (p 0.041)
HR, beats/min 5 2 (p 0.001)Values are mean change  SE.
Abbreviations as in Table 1.or orthostatic hypotension was found, and no events of
ollapse or syncope were reported in the 32 participants with
eadings at baseline and after 3 months of device therapy.
fficacy results. Data on mean change in BP are presented
n Table 2. Office BP measurement shows a significant
ecrease at every visit, with all decrements being highly
ignificant as compared with baseline. Because of several test
ailures, mean 24-h ambulatory BP monitoring recordings are
vice Therapy
f participants are shown in the bars. Means  SE; p values refer to the
ings at baseline and after 3 months of device therapy for 28 participants. Black
circles  diastolic blood pressure (DBP) baseline; red circles  DBP 3 months;
)
dings
 1 Year  2 Years
n  26 n  17
30 6 (p 0.001) 33 8 (p 0.001)
20 4 (p 0.001) 22 6 (p 0.002)
8 2 (p 0.001) 11 4 (p 0.008)
n  15 n  8
13 3 (p 0.001) 24 8 (p 0.017)
8 2 (p 0.001) 13 5 (p 0.049)
6 2 (p 0.012) 11 34 (p 0.005)of De
mber o
re read
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Implantable Device for Baroreflex Activation October 5, 2010:1254–8ot available in all participants but, nevertheless, the data show
odest reductions during the first 3 months of device therapy
nd even significant reductions after 1 and 2 years.
The cohort of declined participants failed to show a
ignificant change in office BP, whereas the mean number of
ntihypertensive agents was slightly increased.
At each visit, the device was temporarily turned off to
ssess the BP level without carotid artery stimulation.
emarkably, BP immediately increased to its baseline levels,
nly to fall again when the device was reactivated.
iscussion
he DEBuT-HT study evaluated the safety and efficacy of
he Rheos system for the treatment of resistant hypertension
n a high-risk patient population. In this first-in-human
tudy, the SAE rate compares favorably with that in the
ublished carotid surgical literature (14,15). It is expected to
ecline as experience with the procedure matures. Most
articipants tolerated the device well and were not encum-
ered by its presence. The SAEs were likely related to the
ubject’s individual risks and comorbidities.
The BP data showed statistically significant mean de-
reases of 21/12 mm Hg after 3 months of Rheos therapy
nd improved further over 2 years of follow-up, with a mean
P reduction of 33/22 mm Hg. The intensity of antihyper-
ensive drug treatment was unchanged, suggesting that the
P changes were related to the device rather than to medical
herapy. Rheos provided a clinically meaningful reduction in
P beyond what was achievable with drug treatment for
hese difficult-to-manage patients.
onclusions
first-in-human evaluation of baroreflex activation therapy
or resistant hypertension has been completed. The Rheos
ystem provided clinically meaningful and sustained reduc-
ions in BP in high-risk patients. The procedure and
herapy demonstrated favorable safety, and each was well
olerated. The programmability of the system allowed ther-
py to be individualized for each subject. This novel
pproach holds promise for patients with resistant hyper-
ension and is currently under evaluation in a prospective,
lacebo-controlled clinical trial.
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